WO2003056024A1 - Procedes de production de la co-enzyme q10 - Google Patents
Procedes de production de la co-enzyme q10 Download PDFInfo
- Publication number
- WO2003056024A1 WO2003056024A1 PCT/JP2002/013766 JP0213766W WO03056024A1 WO 2003056024 A1 WO2003056024 A1 WO 2003056024A1 JP 0213766 W JP0213766 W JP 0213766W WO 03056024 A1 WO03056024 A1 WO 03056024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genus
- organic solvent
- reduced coenzyme
- coenzyme
- production method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/66—Preparation of oxygen-containing organic compounds containing the quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
Definitions
- the present invention provides a compound represented by the following formula (I):
- a reduced coenzyme Q 10 represented by the following formula (II) In the manufacturing method of the oxidized coenzyme Q 1 0 about it represented.
- reduced coenzyme Q is prepared by culturing reduced coenzyme QaQ- producing microorganisms. 70 mol of the total capsidase Q i 0. A microbial cell containing at a ratio of / 0 or more is obtained, and the microbial cell is crushed if necessary. The recovered to a method for producing a reduced form capturing enzyme Q 1 0.
- the present invention also relates to a method for producing an oxidized coenzyme Q, 0, wherein the oxidized coenzyme Q, 0 is subjected to an oxidizing treatment after the recovery.
- Reduced coenzyme Q 10 (I) and oxidized coenzyme Q 10 (II) are components of the mitochondrial electron transport system in cells in human organisms, and are carriers of electrons in oxidative phosphorylation. Is involved in the production of ATP.
- oxidized coenzyme Is used in a wide range of applications as a substance showing excellent pharmacological and physiological effects on various diseases, such as nutritional supplements and cosmetics in addition to pharmaceuticals.
- JP-A-10-330251 discloses a reduced coenzyme.
- An anti-hypercholesterolemia agent, an anti-hyperlipidemic agent, and a therapeutic and prophylactic agent for arteriosclerosis having an excellent cholesterol-lowering effect and having an effective component of cholesterol are disclosed.
- JP-A-10-109333 discloses a reduced coenzyme.
- a pharmaceutical composition having excellent oral absorbability and comprising as an active ingredient is disclosed.
- Antioxidants are also effective as a radical scavenger, Earl 'stocker (R.Stocker) et al., Reduction capturing enzyme Q 0 Gahi preparative L DL of peroxide ct one tocopherol, lycopene and / 3-force (Proceedings of the National Academy of Science of the United States of América), reported that the prevention was more efficient than Rotin (Proceedings of the National Academy of Sciences of the United States of America). Vol. 88, 1646—165 pages, 1991).
- oxidized capture enzyme Q 1 In vivo, oxidized capture enzyme Q 1 . And reduced coenzyme Q. Is a kind of equilibrium, and the oxidized capture enzyme Q absorbed into the living body. / Reduced enzyme Qi. Are known to be mutually reduced and oxidized.
- Another method of reduced coenzyme Q 10 a method of utilizing microbial cells, i.e., reduced coenzyme from reduced coenzyme Q 10 producing microorganism.
- a method of separating and recovering is also considered, but reduced coenzyme Q i produced by the above microbial cells. Indicates many oxidized coenzymes Q. And reduced coenzyme Q! Using a known method. . Separation-recovery is costly.
- reduced coenzyme Q 1 Q is all coenzyme. Of which, if less than 5-10 weight. / 0 , an example in which the content is 30 to 60% by weight in most cases (JP-A-57-70834).
- Pseudomonas cells were extracted by heating with an organic solvent in the presence of sodium hydroxide and pyrogallol, treated with 5% aqueous hydrosanolephite soda, and further dehydrated and concentrated to remove the acetone-soluble part. By collecting the reduced coenzyme Q.
- Example in which an oil containing oil was obtained JP-A-60-75294).
- the above 1) is used photosynthetic bacteria, after cultivation is complicated, in the above-mentioned microbial cells, if intended for production of the reduced capturing enzyme Q 10, all coenzymes.
- the above 2) is an oxidized capture enzyme contained in the hexane phase. Reduced enzyme with hydrosanolefeit soda as a reducing agent. (See Example 3 of JP-A-60-75294), and reduced coenzyme Q in total coenzyme Q0 in a diffuse cell. The ratio of is not clear. In 1) and 2) above, the production amount of coenzyme Q in the culture is not described.
- the microorganism is cultured and reduced coenzyme ⁇ 3 d. High ratio of coenzyme. If you find a way to obtain large amounts of, you can use reduced enzyme. Can be a very advantageous production method.
- SUMMARY OF THE INVENTION-An object of the present invention is a reduced coenzyme. Cultivate productive microorganisms and reduce reduced coenzyme Q t . , A microbial cell containing a high ratio of reduced coenzyme Qi. By suitably recovering, reduced coenzyme. It is an object of the present invention to provide a method for safely and efficiently producing on an industrial scale.
- Another object of the present invention is to provide a reduced coenzyme.
- reduced coenzyme Q obtained 10 microbial cells containing at higher ratios, the enzyme Q 10 capturing original type instead obtained from microorganism cells, oxidized coenzyme Q 10 produced By oxidizing this, the oxidized coenzyme Q! .
- a reduced coenzyme represented by A carbon source, a nitrogen source, a phosphorus source and And reduced nutrients in a medium containing micronutrients By culturing the productive microorganism, reduced coenzyme Q, Is obtained at a ratio of 70 mol% or more of the total coenzyme Q i0, and the microbial cells are crushed as necessary to produce the reduced coenzyme Q! . And extracting the reduced coenzyme Q 0 with an organic solvent.
- reduced coenzyme Q i Q is replaced by total coenzyme Q i.
- microbial cells containing at least 70 mol% are obtained, and the microbial cells are crushed, if necessary, to produce reduced coenzyme Qi.
- microorganism culturing reduced coenzyme.
- the reduced coenzyme Q! Can be produced on an industrial scale at low cost.
- the oxidized coenzyme Q 1 0 may also be prepared by a simple operation.
- these coenzymes produced by microorganisms. Is basically free of the (Z) -isomer and can obtain the same (a111-E) -isomer as that contained in meat, fish and the like.
- reducing coenzyme Q 1 o is the total coenzyme Q.
- Microbial cells containing are essentially reduced coenzymes. The whole coenzyme. Of the microorganisms which can be produced at a ratio of 70 mol% or more, preferably 75 mol% or more.
- Microorganisms are all coenzymes.
- Uruka generated reduced coenzyme Q 10 in any ratio for example, using a test tube (inner diameter 21 mm, total length 2 O Omm), a microorganism 1 OiriL medium [(glucose 20 g, peptone 5 g Yeast extract 3 g, malt extract 3 g) / L, pH 6.0], and shake culture (amplitude 2 cm, 310 reciprocations / min) for 72 hours at 25 ° C can be evaluated.
- Preferred culture conditions for fermentation production on an industrial scale will be described later, but the culture conditions described above are reduced coenzymes that the microorganism has as its ability. This is one way to standardize the ratio to reflect it within a large, error-free range.
- reduced capture enzyme there are all coenzymes. Among them, microbial cells having a content of 70 mol% or more, preferably 75 mol% or more are preferably used in the present invention. In addition, more preferably, a reduced-type capture enzyme per medium under the above culture conditions. It is preferable to use a microorganism having a production capacity of usually l / ig / mL or more, preferably 2 ⁇ gZmL or more.
- reduced coenzyme Q 10 content of the, and, all capturing the enzyme reduced coenzyme in.
- the ratio can be confirmed by physically crushing the microbial cells, extracting them with an organic solvent, and performing HP LC analysis. Specifically, it is measured by the following procedure.
- the obtained result is the reduced enzyme Qi.
- Reduced coenzyme Q that reflects the ratio as accurately as possible and that can be guaranteed at a minimum! .
- This method has been found by some experiments of the present inventors to be an easy and appropriate method to carry out.
- any of bacteria, yeast, and mold can be used without limitation.
- the microorganisms include, for example, genus Agrobacterium, genus Aspergillus, genus Acetobacter, genus Aminobacter, genus Agromonas, and Acidiphilium Genus, genus Breromyces, genus Bullera, genus Brevundimo nas, genus Cryptococcus, genus Chionospha era, genus Candida cerinus, Serinos Genus, Exisophiala, genus Exobasidimn, genus Filomyces, genus Filobasidiella, genus Filobasidium, genus Geophihum, Geotrichum, Geotrichum Genus (Gluconobacter), Genus Kockovaella, Genus Tanolec (Kurtzmanomyces), Genus Lalaria, Gen
- Genus genus Saitoella, genus Schizosaccharomyces, genus Sphingomonas, genus Sporotrichum, genus Sympodiomycopsis, Sterigmato igs , Tough The genus Tapharina, the genus Tremella, the genus Trichosporon ⁇ The genus Tilletiaria, the genus Tilletia, the genus Triplysporium (Tolyposporium), the genus Tilletiopus tila, The genus Udeniomyce, the genus Xanthophllomyces, the genus Xanthobacter, the genus Paecilomyces, the genus Acremonium, the genus Hyomonus zobium R Bacteria (preferably non-photosynthetic bacteria) and yeasts are preferred from the viewpoint of easiness of culture and productivity.
- bacteria include the genus Agrobacterium, The genus Gluconobacter, etc. is used in yeast, and Schizosaccharomyces (Schizosaccharomyces) is used in yeast. genus charomyces) and genus Saitoella.
- Preferred species include, for example, Agrobacterium tumefacience IF013263, Agrobacterium 'radipactor (A grobacterium radiobacter ATCC4718), Aspergillus clavatus (Aspergillus clavatus JCM1718 pat. (Acetobacter xylinum I F015237), Aminobacter aganouensis JC M7854, Agromonas oligotrophica JCM1494, Acidophilus Multibrum alba, Acidiphilium multivorum J.
- Rhodotonerella ⁇ Rhodotorala glutin is IF0387 Jodopobatum (Rhodosporidium diobovatum ATCC1830), Rhizomonas suberifaciens IF015212, Rhodobium orients (Rhodobium orients JC 9337), Rhodoplanes' elegance (Mod oplanes elegans J ⁇ ⁇ 0 ⁇ ⁇ ⁇
- Paphiopegyri (Sympodiomycopsis paphiopedili JCM8318), Sterigmatosporidium 'Polymonorefa (Sterigmatosporidium polymorphum IFO10 121), Sphingomonas ⁇ Adhesiba (Sphingomonas) adhesiva JCM7370), Tafarina 'force Errescens (Tapharina caerulescens CBS351.35), Tremella-mesenteric force (Tremella mesenterica ATCC24438), Trichosporon-cutaneum (Trichosporon cutaneum IF01198), Chiretialia-Anomala ti anomala ti anomala ti anomaloma , Tilletia caries JCM1761, Tolyposporium bullatum JCM2006, Tilletiopsis- ⁇ sintonesis (Tilletiopsis washintonesis CBS544), Ustirago 's
- Rizobiumu 'Merotti (Rhizobium meliloti ATCC9930) can be mentioned.
- the reduced coenzyme Q 1 0 producing microorganism not only the wild-type strain of the microorganism, for example, reduced coenzyme Q E of the above microorganisms.
- Microorganisms in which the transcription and translation activities of genes involved in biosynthesis or the enzymatic activities of expressed proteins are modified or improved can also be used preferably.
- Modification or improvement of gene transcription and translation activity, or enzyme activity of expressed protein Means for carrying out this method include genetic recombination (including improvement, amplification, and rupture of self-genes, introduction of a foreign gene and improvement and amplification of the gene), and mutagenesis using a mutagen. Mutagenesis is preferred.
- More preferred microorganisms that can be used in the present invention are reduced coenzyme Qe when the above-mentioned modified or improved microorganism, preferably a microorganism that has been mutagenized with a mutagen, is evaluated by the above-described culturing method and measuring method.
- It is a microorganism having a content of at least / 0 , particularly preferably at least 90 mol%.
- reduced coenzyme per culture medium is additionally required.
- Production capacity of 1 g ZmL or more preferably 2 ⁇ g ZmL or more, more preferably 3 / zg ZmL or more, still more preferably 5 ⁇ g ZmL or more, particularly preferably 10 ⁇ g / m2. It is preferable to use a microorganism having a production capacity of not less than L, particularly preferably not less than 15 ⁇ g Zml, most preferably not less than 20 g / ml.
- Mutagenesis can be performed as a single mutagenesis, but it is preferred to perform more than one mutagenesis. This is because the ability to produce a reduced form capturing enzyme Q 1 0 by each mutagenesis step was found to be improved.
- the reduced coenzyme Qi is as high as possible when evaluated by the above-described growth method and measurement method. Needless to say, those having production capacity are preferable.
- the mutagenesis treatment can be performed using any appropriate mutagen.
- the term “mutagen” in a broad sense includes not only drugs having a mutagenic effect, for example, but also treatments having a mutagenic effect such as UV irradiation.
- suitable mutagens include ethyl methanesulfonate, UV irradiation, nucleotide base analogs such as N-methyl-N'-nitro-N-nitrosoguanidine, promouracil, and acridines.
- the present invention is not limited to this.
- mutagenesis is followed by a high reduced coenzyme.
- high productivity of reduced coenzyme Q 1 0 in the fermentative production on an industrial scale in part, the reduced coenzyme.
- the whole coenzyme. Obtained by the use of microbial cells containing 7 0 mol% or more ratio of, also, in part, of the order to increase the production capacity of the reduced coenzyme Q 1 0 per medium described below Obtained by using suitable culture (fermentation) conditions. It is particularly preferred to combine the use of the preferred microbial cells described above with the use of the following preferred culture (fermentation) conditions.
- the cultivation is usually carried out in a medium containing macro and micronutrients suitable for the growth of the microorganism.
- the nutrients include, for example, carbon sources (eg, glucose, sucrose, maltose, starch, corn syrup, molasses and other carbohydrates; alcohols such as methanol, ethanol, etc.), nitrogen sources (eg, corn steep liquor, ammonium sulfate).
- phosphorus sources eg, ammonium phosphate, phosphoric acid, etc.
- micronutrients eg, magnesium, potassium, zinc, copper, iron, manganese
- Minerals such as molybdenum, sulfuric acid, and hydrochloric acid; vitamins such as biotin, desthiobiotin, and vitamin B1; amino acids such as alanine and histidine; and natural materials containing vitamins such as yeast extract and malt extract). But are not limited to these It can be used to be used for.
- the components of the natural medium such as yeast extract also contain a phosphorus source such as phosphate. The above nutrients are used in appropriate combinations.
- the temperature for the culture is usually 15 to 45 ° C, preferably 20 to 37 ° C. Below 15 ° C, the growth rate of microorganisms tends to be low to be acceptable for industrial production, and at temperatures above 45 ° C, the survival of microorganisms tends to be impaired.
- The: H of the culture is usually: -9, preferably 5-8. At H3 or less and pH10 or more, the growth of microorganisms tends to be easily inhibited.
- the concentration of the carbon source (including the alcohol formed), substantially reduced coenzyme Q 1 0 capacity It is preferable to control the concentration so as not to adversely affect the image quality. Therefore, the concentration of the carbon source in the culture solution is reduced coenzyme. It is preferable to control the culture so that the concentration does not substantially adversely affect the production capacity, that is, usually 20 g ZL or less, preferably 5 g / L or less, more preferably 2 g / L or less. .
- the concentration of the carbon source it is preferable to employ a fed-batch culture method.
- the supply of nutrients based on culture management indicators such as pH, dissolved oxygen concentration (DO) or residual sugar concentration
- DO dissolved oxygen concentration
- the carbon source concentration in the culture solution it can.
- the supply of nutrients may be started from the beginning of the culture or may be started during the culture.
- the supply of nutrients can be continuous or intermittent.
- the above-mentioned carbon source is separated from other components and supplied to the medium (separately).
- Culture is performed using the desired reduced coenzyme Qi. It can be terminated when the production volume reaches.
- the culturing time is not particularly limited, but is usually 20 to 200 hours.
- the above culture is usually performed aerobically.
- the term “aerobic” means that oxygen is supplied so that oxygen limitation (oxygen deficiency) does not occur during culture.
- oxygen limitation is performed during culture. It means that the supply of oxygen is sufficient so that it does not substantially occur.
- the cultivation is usually performed under aeration, preferably under aeration and stirring.
- a reduced coenzyme can be obtained by using the microorganisms and culture conditions as described above.
- the total capture enzyme Qi Among them, microbial cells containing at least 70 mol%, preferably at least 75 mol% can be obtained. Also, reduced coenzyme. Also yields a high value of 1 g / mL or more, preferably 2 ⁇ g / mL or more, and more preferably 3 g / mL or more.
- the reduced coenzyme Q i0 is recovered by extraction from the microbial cells obtained by the above culture using an organic solvent. Upon extraction, the cells can be crushed if desired. Cell disruption contributes to efficient extraction of the enzyme Q 1 0 capturing production ⁇ accumulated reduction in the cell. Needless to say, cell disruption and extraction may be performed simultaneously.
- a reduced coenzyme is used. It is sufficient that the surface structure such as the cell wall is damaged to such an extent that the microorganism can be extracted, and it is not always necessary to break or fragment the microbial cells.
- yeast yeast molds usually require cell disruption treatment, and if the cells are not disrupted, reduced enzyme produced and accumulated in the cells. Is difficult to collect efficiently.
- the microbial cells are crushed by performing one or several of the following crushing methods in an arbitrary order.
- Examples of the crushing method include, in addition to physical treatment, chemical treatment, and enzymatic treatment, heat treatment, autolysis, osmotic lysis, and plasmolysis.
- Examples of the physical treatment include use of a high-pressure homogenizer, an ultrasonic homogenizer, a French press, a pole mill, and the like, or a combination thereof.
- Examples of the chemical treatment include a treatment using an acid (preferably a strong acid) such as hydrochloric acid or sulfuric acid, a treatment using a base (preferably a strong base) such as sodium hydroxide or a hydroxylating lime, and the like. Combinations can be mentioned.
- an acid preferably a strong acid
- a base preferably a strong base
- Examples of the enzymatic treatment include a method using lysozyme, zymolyase, dalcanase, nopozyme, protease, cellulase and the like, and these may be used in combination as appropriate.
- Examples of the heat treatment include a treatment at 60 to 100 ° C. for about 30 minutes to 3 hours.
- Examples of the self-digestion include treatment with a solvent such as ethyl acetate.
- osmotic lysis and cytoplasmic lysis in which cells are broken by treating the cells with a solution different from the intracellular salt concentration, may not be sufficient in this method alone.
- the cell disruption method as a pretreatment for the extraction and recovery of the cells includes physical treatment, chemical treatment (particularly acid treatment, and preferably strong acid (for example, pKa of 2.5 in an aqueous solution. acid treatment) or heat treatment under conditions that the reduced coenzyme Q 1 0, as described below has been protected from oxidation reaction lay preferred by the following acids), more preferably physical treatment in terms of crushing efficiency.
- the morphology of the microbial cells used for the cell disruption described above includes a culture solution, a concentrated culture solution, a sample obtained by collecting microbial cells from a culture solution as wet cells, a wash of these cells, and a wet cell as a solvent (for example, Suspended in water, physiological saline, buffer, etc.), dried cells obtained by drying the wet cells described above, and dried cells in a solvent (eg, water, physiological saline, buffer solution, etc.). ), But is preferably an aqueous suspension of living cells, and more preferably from the viewpoint of operability and the like, more preferably a culture solution, a concentrated culture solution, It has been washed.
- the form of the microbial cells or the crushed cells used for the extraction and recovery of the microorganisms is not particularly limited, as described above, and may be wet cells or dried cells of the microbial cells or the crushed cells. Is an aqueous suspension of microbial cells or a crushed cell thereof, more preferably a culture solution, a concentrated and / or washed culture solution, or a crushed solution of these (all aqueous suspensions) .
- the concentration of the cells in the above-mentioned microorganism cells or the suspension of the crushed cells is not particularly limited, and may be usually 1 to 25% by weight on a dry weight basis, but is economically 10 to 20% by weight. Preferably, the amount is%.
- the microbial cells and the cell crushed product obtained in this manner are treated with an organic solvent. By performing the extraction, reduced coenzyme Q i 0 can be recovered.
- organic solvent used for extraction examples include hydrocarbons, fatty acid esters, ethers, alcohols, fatty acids, ketones, nitrogen compounds (including nitriles and amides), and sulfur compounds. Can be.
- reduced coenzyme Q In the extraction of water, it is preferable to use at least one of hydrocarbons, fatty acid esters, ethers and nitriles as an extraction solvent from the viewpoint of protection from oxidation by molecular oxygen. Hydrogens and fatty acid esters are preferred, and hydrocarbons are most preferred.
- hydrocarbons examples include, but are not particularly limited to, aliphatic hydrocarbons, aromatic hydrocarbons, and halogenated hydrocarbons. Aliphatic hydrocarbons and aromatic hydrocarbons are preferred, and aliphatic hydrocarbons are more preferred.
- the aliphatic hydrocarbon may be cyclic or non-cyclic, saturated or unsaturated, and is not particularly limited. In general, a saturated hydrocarbon is preferably used. Usually, those having 3 to 20 carbon atoms, preferably 5 to 12 carbon atoms, more preferably 5 to 8 carbon atoms are used.
- Specific examples include, for example, propane, butane, isobutane, pentane, 2-methyl ⁇ / butane, hexane, 2-methinolepentane, 2,2-dimethylbutane, 2,3-dimethylbutane, heptane, heptane isomers (eg, , 2-Methylhexane, 3-Methyl / Lexane, 2,3-Dimethinolepentane, 2,4-Dimethinolepentane), Octane, 2,2,3-Trimethylpentane, Isooctane, Nonane, 2,2, 5-trimethylhexane, decane, dodecane, 2-pentene, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, cyclopentane, methinolecyclopentane, cyclohexane, methinolecyclohexan
- pentane, 2-methylptane, hexane, 2-methyl / lepentane, 2,2-dimethylinobutane, 2,3-dimethylbutane, heptane, and heptane isomers eg, 2-methylhexane, 3-methylethane) Hexane, 2,3-dimethinolepentane, 2,4-dimethylpentane), octane, 2,2,3-trimethylpentane, isooctane, cyclopentane, methinole cyclopentane, cyclohexane, methinolecyclohexane, ethinolecyclo Hexane and the like.
- heptane and heptane are preferably used. More preferably, pentanes having 5 carbon atoms (such as pentane), hexanes having 6 carbon atoms (such as hexane and cyclohexane), and heptane having 7 carbon atoms (such as heptane and methylcyclohexane) Hexane, etc.). Particularly preferred are heptane (eg, heptane, methylcyclohexane, etc.), and most preferred is heptane, since the protective effect against oxidation is particularly high.
- pentanes having 5 carbon atoms such as pentane
- hexanes having 6 carbon atoms such as hexane and cyclohexane
- heptane having 7 carbon atoms such as heptane and methylcyclohexane
- the aromatic hydrocarbon is not particularly limited, but usually has 6 to 20 carbon atoms, preferably 6 to 12 carbon atoms, and more preferably 7 to 10 carbon atoms.
- Specific examples include benzene, tonolene, xylene, o-xylene, m-xylene, p-xylene, ethynolebenzene, cumene, mesitylene, tetralin, ptynolebenzene,: —cymene, cyclohexyl / madzene, getinole Benzene, pentylbenzene, dipentinolebenzene, dodecinolebenzene, styrene and the like can be mentioned.
- More preferred are toluene, xylene, o-xylene, m-xylene, p-xylene, cumene, tetralin and the like. Most preferred is cumene.
- the halogenated hydrocarbon may be cyclic or non-cyclic, saturated or unsaturated, and is not particularly limited. Generally, non-cyclic halogenated hydrocarbons are preferably used. More preferred are chlorinated hydrocarbons and fluorinated hydrocarbons, and even more preferred are chlorinated hydrocarbons. Further, those having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, and more preferably 1 to 2 carbon atoms are suitably used.
- Specific examples include, for example, dichloromethane, chloroform, carbon tetrachloride, 1,1-dichloroethane, 1,2-dichloroethane, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1,1,2-Tetrachloroethane, 1,1,2,2-Tetrachloroethane, Pen'tachloroethane, Hexachloroethane, 1,1-Dichloroethylene, 1,2-Dichloroethylene , trichlorethylene, tetrachlorethylene, 1, 2-dichloroethane port Purono ⁇ 0 emissions, 1, 2, 3-trichloro port Purono ⁇ 0 down, black hole benzene, 1, 1, 1, and 2-Tetorafuruo port ethane .
- dichloromethane chloroform, tetrachloride, 1,1-dichloroethane, 1,2-dichloroethane, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1,2-trichloroethane, Examples include 1-dichloroethylene, 1,2-dichloroethylene, trichloroethylene, chlorobenzene, 1,1,1,2-tetrafluoroethane. More preferred are dichloromethane, chlorophonolem, 1,2-dichloroethylene, trichloroethylene, cyclobenzene, 1,1,1,2-tetrafluoroethane and the like.
- the fatty acid esters are not particularly limited, but include, for example, propionate, acetate, formate and the like. Preferred are acetate and formate, and more preferred are acetate.
- the ester group is not particularly limited, but is usually an alkyl ester having 1 to 8 carbon atoms, an aralkyl ester having 7 to 12 carbon atoms, preferably an alkyl ester having 1 to 6 carbon atoms, and more preferably an alkyl ester having 1 to 6 carbon atoms. An alkyl ester having 1 to 4 carbon atoms is used.
- propionate esters include, for example, methyl propionate, ethyl propionate, butyl propionate, isopentyl propionate and the like. Can be. Preferred is ethyl propionate.
- acetate esters include, for example, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isoptyl acetate, sec-butyl acetate, pentyl acetate, isopentyl acetate, sec-hexyl acetate, cyclohexanol acetate. And benzyl acetate.
- formate esters include, for example, methyl formate, ethyl formate, propyl formate, isopropyl formate, butyl formate, isoptyl formate, sec-butyl formate, pentyl formate, and the like.
- Preferred are methyl formate, ethyl formate, propyl formate, butyl formate, isoptyl formate, pentyl formate and the like. Most preferred is ethyl formate.
- the ethers are not particularly limited, regardless of whether they are cyclic or acyclic, or saturated or unsaturated, but generally, saturated ethers are preferably used. Usually, those having 3 to 20 carbon atoms, preferably 4 to 12 carbon atoms, more preferably 4 to 8 carbon atoms are used. Specific examples include getyl ether, methyl tert-butyl ether, dipropyl ether, diisopropyl ether, dibutinole ether, dihexyl ether, ethyl vinyl ether, butyl vinyl ether, aesone, and phenene.
- Tonole Petinolepheninoleatenole, Methoxytoluene, Dioxane, Furan, 2-Methylfuran, Tetrahydrofuran, Tetrahydrodropyran, Ethylene glycolone Dimethylatenole, Ethylene glycol jeteinoatenole, Etylene glycol Examples include ethylene glycolone monomethyzooleate, ethylene glycolone monomethyzooleate, ethylene glycolone monoethylenate, and ethylene glycolone monoenotinoleatene.
- getinoleether More preferably, they include getinoleether, methinole tert-butylenoate ethere, aniso monoleate, dioxane, tetrahydrofuran, ethylene glycolone monomethinoleate ethere, and ethylene glycol monoethyl ether. More preferred are getyl ether, methyl tert-butyl ether, anisol and the like, and most preferred is methinolle tert-butyl / leatenole.
- the alcohols may be cyclic or non-cyclic, saturated or unsaturated, and are not particularly limited. In general, saturated alcohols are preferably used. Usually, it has 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, and more preferably 1 to 6 carbon atoms. Of these, monohydric alcohols having 1 to 5 carbon atoms, dihydric alcohols having 2 to 5 carbon atoms, and trihydric alcohols having 3 carbon atoms are preferable.
- these alcohols include, for example, methanol, ethanol, 1-propanol, 2-propanol, 1-ptanol, 2-butanol, isoptinoleanol, tert-butynoleano Reconore, 1-pentano-1-nore, 2-pentano-nore, 3-pentanono-nore, 2-methyl-1-butanol, isopentino-leno-nocole, tert-pentino-leno-no-reno, 3-methinole 2-butanol , Neopen chinoreanorekonore, 1-hexanore, 2-methinole 1-pentanole, 4-methyl 2-pentanol, 2-ethyl-1-1-ptanole, 1-heptanoone, 21-heptanole , 3-Heptano-nore, 1-Octano-nore, 2-Octano-no-re,
- Preferred examples of the monohydric alcohol include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, isobutynoleanol, tert-butyl alcohol, 1-pentanol and 2-pentanol. Nore,
- 3-Pentanol 2-Methylenol 1-Ptanolone, Isopentynole alcohol, tert-Pentinoleanole cone, 3-Methinole-1-butanol, Neopentine / Leanole coneole, 1-hexanol, 2-Methylenole 1-pentanole 1-hole, 4-methinole 2-pentanol, 2-ethyl-1 butanol, 1-heptanol, 2-heptanol, 3-heptanol, 1-oktananol, 2-octanol, 2-etch / ray 1 1-hexanol, 1-nonanol, 1-decanol, 1 pendanol,
- methanol ethanol
- 1-propanol 2-propanol
- 2-propanol 1-butanol
- 2-butanol isobutyl alcohol
- 2-methyl-1-butanol isopentyl alcohol, etc.
- 2-propanol 2-propanol.
- dihydric alcohol 1,2-ethanediol, 1,2-propanediol, 1,3-propanediol and the like are preferred, and 1,2-ethanediol is most preferred.
- Glycerin is preferred as the trihydric alcohol.
- fatty acids examples include formic acid, acetic acid, propionic acid and the like. Preferably, it is formic acid or acetic acid, most preferably acetic acid.
- Ketones are not particularly limited, and those having 3 to 6 carbon atoms are preferably used. Specific examples include, for example, acetone, methyl ethyl ketone, methyl butyl ketone, methyl isobutyl ketone, and the like. Preferably, they are acetone and methyl ethyl ketone, and most preferably, acetone.
- the etryl is not particularly limited, regardless of cyclic or non-cyclic, or saturated or unsaturated, but saturated is generally preferably used. Usually, those having 2 to 20 carbon atoms, preferably 2 to 12 carbon atoms, more preferably 2 to 8 carbon atoms are used.
- acetonitrile for example, acetonitrile, propionitrile, malononitrile, ptyronitrile, isopyronitrile, succinonitrinole, valeroletrinole, gnorethalonitrile, hexanetrilinole, and heptylcyanide.
- Octylcyanide decanecanitrile, dodecanenitrile, tridecanenitrile, pentadecane-tolyl, stearonitrinole, chloroacetonitrile, bromoacetonitrile, chloropropionitole, bromopropiolinee, methoxyacetonitrile Methyl anoacetate, ethyl cyanoacetate, tolunitrile, benzo-tolyl, benzobenzonitrile, bromobenzonitrile, cyanobenzoic acid, nitrobenzonitrile, anisonitrile, phthalonitrile , Bromotonolenitrile, methyl cyanobenzoate, methoxybenzonitrile, acetylbenzonitrile, naphthotrile, biphenylcarbonitrile, phenylpropionitrile, phenylbutyrate-tolyl, methylfurineacetonitrile, diphenacenitritoletrynitrile,
- acetonitrile Preferably, it is acetonitrile, propionitrile, succinonitrile, petit mouth nitrile, isobutyrate-tolyl, valeronitrile, methyl cyanoacetate, ethyl cyanoacetate, benzonitrile, tonorenitrile, and clomouth propionitrile. More preferred are acetonitrile, propionitrile, ptyronitrile, isopyronitrile, and most preferred is acetonitrile.
- nitrogen compounds other than nitriles include amides such as formamide, N-methylformamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, and the like.
- amides such as formamide, N-methylformamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, and the like.
- Tromethane, triethylamine, pyridin and the like can be mentioned.
- sulfur compounds examples include dimethyl sulfoxide, sulfolane and the like.
- boiling point e.g., appropriate heating to increase solubility, and easy removal of solvent from wet bodies and recovery of solvent from crystallization filtrate, etc.
- Boiling point approximately 30 to 150 ° C at 1 atm, melting point that hardens to solidify when handled at room temperature and when cooled below room temperature (above about 0 ° C, preferably about 10 ° C, (Preferably about 20 ° C or more) and low viscosity (about 10 ° C or less at 20 ° C)).
- the oxidation protective effect of the reduced coenzyme Tends to increase in highly concentrated solutions of Reduced coenzyme. Has a high solubility in the above-mentioned organic solvents (eg, hydrocarbons, fatty acid esters, etc.) having a high oxidation protection effect. This high solubility enables handling in highly concentrated solutions, Subsidies.
- the preferred extraction time of concentration for the oxidation protective effects of reduced capturing enzyme Q 1 0 is not limited in particular, as the concentration of reduced coenzyme Q 1 0 for the organic solvent, usually 0.0 0 1 wt %, Preferably at least 0.1% by weight, more preferably at least 0.1% by weight.
- the upper limit is not particularly limited, but is usually 10% by weight or less.
- the extract ⁇ recovering the enzyme Q 1 0 catching reduced form have preferably to use a hydrophilic organic solvent. Specific examples include acetone, acetonitrile, methanol, ethanol, 1-propanol, 2-propanol and the like.
- the extract ⁇ recovering the enzyme Q 1 0 catching reduced form rather preferably to use a hydrophobic organic solvent, which Aids in the removal of water-soluble substances derived from microorganisms.
- Most of the hydrophobic organic solvents are organic solvents having a high oxidation protection effect as described above, which is extremely convenient.
- hydrophobic organic solvent hydrocarbons, fatty acid esters, and ethers are preferable.
- an organic solvent is used from an aqueous suspension of microbial cells or the crushed cell, particularly an aqueous suspension of the crushed cell, especially an aqueous suspension of the crushed cell by physical treatment.
- an aqueous suspension of the crushed cell especially an aqueous suspension of the crushed cell by physical treatment.
- hydrophilic organic solvent as an auxiliary solvent in addition to the hydrophobic organic solvent as the extraction solvent.
- the hydrophobic organic solvent is not particularly limited, and the above-mentioned ones can be used, but hydrocarbons are preferable, and aliphatic hydrocarbons are more preferable.
- the aliphatic hydrocarbons those having a coal number of 5 to 8 are preferably used.
- aliphatic hydrocarbon having 5 to 8 carbon atoms include, for example, pentane, 21-methyl / lebutane, hexane, 2-methinolepentane, 2,2-dimethinolebutane, 2,3-dimethylbutane, heptane, heptane Isomers (eg, 2-methylhexane, 3-methylhexane, 2,3-dimethinolepentane, 2'4-dimethinolepentane), octane, 2,2,3-trimethinolepentane, isooctane, cyclo Pentane, methinolecyclopentane, cyclohexane, meth / lecyclohexane, ethynolecyclohexane and the like can be mentioned. Particularly preferred are hexane, heptane and methylcyclohexane, and most preferred are
- the hydrophilic organic solvent used in combination with the above-mentioned hydrophobic organic solvent is not particularly limited, and the above-described ones can be used, but alcohols are preferable. Among alcohols, monohydric alcohols having 1 to 5 carbon atoms are preferably used.
- Particularly preferred are methanol, ethanol, 1-propanol and 2-propanol, and most preferred is 2-propanol.
- the amount of the hydrophilic organic solvent and the hydrophobic organic solvent is not particularly limited, but the concentration at the time of extraction is preferably 5 to 50% based on the volume of the whole solution. % By volume, and the hydrophobic organic solvent ranges from 25 to 65% by volume.
- the temperature at the time of extraction is not particularly limited, but is usually 0 to 60 ° C, preferably 20 to 50 ° C.
- Either batch extraction or continuous extraction can be used as the extraction method, but continuous extraction (preferably, multistage countercurrent extraction) can be used.
- the stirring time in batch extraction is not particularly limited, but is usually 5 minutes or more.
- the average residence time in continuous extraction is not particularly limited, but is usually 10 minutes or more.
- Reduced coenzyme When recovering, reduced coenzyme. It is preferable to take care not to decompose (eg, not oxidized to oxidized coenzyme).
- the above extraction is preferably performed under acidic to weakly basic conditions, preferably under acidic to neutral conditions.
- pH When pH is used as an index, it depends on the contact time, but it is pH 10 or less, preferably pH 9 or less, more preferably pH 8 or less, and still more preferably pH 7 or less.
- the oxidation reaction can be substantially protected.
- the above-mentioned cell crushing and / or Z extraction or extraction is carried out under conditions where reduced coenzyme 0 is protected from the oxidation reaction. Is preferred. More preferably, at least the above extraction is performed under such conditions, and more preferably, the above crushing and extraction are performed.
- condition protected from the oxidation reaction examples include, for example, under a deoxygenated atmosphere (under an inert gas atmosphere such as a nitrogen gas, a carbon dioxide gas, a helium gas, an argon gas, a hydrogen gas, a reduced pressure, a boiled Ji blue, Under conditions of high salt concentration, for example, preferably when the concentration of salts in the aqueous phase (eg, inorganic salts such as sodium chloride and sodium sulfate) is about 5% or more.
- a strong acid eg, an acid having a pKa of 2.5 or less in an aqueous solution
- a reduced coenzyme for example, a reduced coenzyme.
- the present invention also provides an oxidized coenzyme after subjecting the microbial cell or the crushed cell to an oxidation treatment. Is extracted with an organic solvent, or reduced coenzyme Q i is obtained from the microbial cells or the crushed cells. Is extracted with an organic solvent and, if necessary, subjected to a purification treatment, and then subjected to an oxidation treatment to obtain an oxidized coenzyme. Can be manufactured.
- the oxidation may be carried out, for example, by using reduced coenzyme Q 1 Q (preferably, a microbial cell containing reduced coenzyme Q i described above, an aqueous suspension of the cell lysate, or reduced coenzyme Q 1) . And an oxidizing agent (eg, manganese dioxide), and the mixture is treated at room temperature (eg, 30 ° C.) for 30 minutes or more.
- an oxidized enzyme is used.
- it can be performed in the same manner as the extraction operation of the enzyme Q 1 0 catching the reduced form of the above-mentioned, it'll Ri oxidized coenzyme. Can be efficiently collected.
- oxidized coenzyme Q 1 does not need to conduct a "under the conditions protected from oxidation reaction", as recommended in the recovery of the reduced capturing enzyme Q 1 0, normal safe operation and the like Should be taken into consideration.
- the oxidized capture enzyme Q thus obtained. May be purified by column chromatography or the like, if desired.
- Type coenzyme Q i. It can be obtained as crystals.
- FIG. 1 is a schematic view of a countercurrent three-stage continuous extraction device used in Example 8. BEST MODE FOR CARRYING OUT THE INVENTION
- Mouth do Tonerella ⁇ Rhodotomla glutinis IF01125 is aerobically grown at 25 ° C in medium (5 g of peptone, 3 g of yeast extract, 3 g of manoleto extract, 20 g / L of gnorecose, pH 6.0). The cells were cultured for 8 hours. After culturing, the cells are collected by centrifugation, and N-methyl-N'-nitro-2-N-trotroguanidine is added to a concentration of 200 ⁇ g / mL. In pH 7 phosphate buffer. After 1 hour at 25, the cells were washed 5 times with 0.9% NaCl solution and resuspended in 0.9% NaCl solution.
- the cell suspension was diluted appropriately to form colonies on the agar plate of the above medium.
- the ratio of reduced coenzyme Q x Q were examined in the same manner as in Example 1.
- a mutant strain having a productivity of 15 g / mL or more was obtained by repeating the mutation 10 times.
- the reduced coenzyme at this time. was 80 mol% or more.
- Cytoella, Saitoella complicata IFO 10748 is aerobically grown at 25 ° C in a medium (5 g of peptone, 3 g of yeast extract, 3 g of malt extract, 20 g / L of glucose, pH 6.0).
- a medium 5 g of peptone, 3 g of yeast extract, 3 g of malt extract, 20 g / L of glucose, pH 6.0.
- the obtained cells were crushed twice at a crushing pressure of 80 MPa using a Lanie pressure type homogenizer sealed with nitrogen gas to prepare a cell lysate. Extraction was repeated three times from the cell lysate at a ratio of 30 parts by volume of isopropanol and 40 parts by volume of hexane to obtain an extract.
- the extraction rate was 99% and reduced coenzyme.
- Mouth dotorula ⁇ Glutinis (Rhodotomla glutinis)
- darcos When cultivating aerobically at 25 ° C with 0 L (10 g of peptone, 5 g of yeast extract, 3 g of malt extract, 20 g / L of glucose, pH 6.0), darcos should be obtained after 48 hours. By the 96th hour at a rate of 4 g Z hour, the mixture was fed (a fed glucose amount of 190 g).
- the production amount of reduced enzyme Q 1 Q per medium is 20 g / mL or more, and the amount of reduced enzyme is reduced.
- Example 3 The extract obtained in Example 3 was replaced with a hexane solution, adsorbed to a column filled with silica gel, and developed and eluted with an n- hexane / getyl ether (9Z1) solution. And reduced coenzyme. Was obtained. This fraction was further cooled to 2 QC with stirring to obtain a white slurry. All the above operations were performed in a nitrogen atmosphere. The obtained slurry was filtered under reduced pressure, the wet crystals were washed with the above developing solution (the temperature of the solvent used for washing was 2 ° C), and the wet crystals were dried under reduced pressure (20 to 40 ° C, 1 to 30 mmHg). ) To obtain 81 mg of white dry crystals. The purity of the obtained crystals is 99.9%, reduced coenzyme. Was 90 mol%.
- Example 3 The extract obtained in Example 3 was replaced with n-hexane, manganese dioxide (5 Omg) was added, and the mixture was stirred at 30 ° C for 30 minutes. This reaction solution was fractionated and purified as in Example 5 to obtain high-purity oxidized coenzyme Q. 74 mg was obtained.
- Cytoella 'Saitoella complicata IFO 10748 in medium (5 g of peptone, 3 g of yeast extract, 3 g of masoleto extract, g / recose 20 g / L, ⁇ H6.0) at 25 ° C for 72 hours
- the culture was performed 50 OmL aerobically.
- the obtained cells were crushed twice at a crushing pressure of 80 MPa using a pressure-type homogenizer manufactured by LaEye sealed with nitrogen gas to prepare a cell lysate.
- Reduced coenzyme in crushed stone fluid Percentage of total coenzyme, including oxidized form. 97%.
- Isopropanol and n-hexane were mixed with 20 mL of the cell lysate at a ratio shown in the column of the first extraction in Table 4 below so that the total amount of the solvent was 500 mL, and the temperature was 40 ° C. C.
- the mixture was stirred for 30 minutes, and the first extraction operation was performed. After completion of the extraction, the mixture was allowed to stand for 10 minutes, and the separated upper layer was separated.
- the volume ratio of the lower layer (residue) to the total liquid volume at this time was used as an index of separation, and is shown in Table 4 as the interface position.
- the solvent concentration of the residue layer was measured, and isopropanol and hexane were added so that the total solvent ratio was the ratio shown in the second column of Table 4.
- the mixture was stirred at a temperature of 40 ° C for 30 minutes. Then, let stand for 10 minutes, separate the upper layer in the same manner as above, measure the solvent concentration of the residue layer, and use isopropanol so that the total solvent ratio becomes the ratio shown in the third column of Table 4. And add hexane, temperature 25 The mixture was stirred at 30 ° C. for 30 minutes to perform the third extraction operation.
- Table 4 shows the calculation results.
- the static separation was good, and the total extraction rate after three extractions was 90% or higher, indicating a high recovery rate.
- the isopropanol concentration was set to 30% or more, a high recovery rate of 99 ° / 0 or more was obtained.
- Saitoella complicata IFO 10748 in medium (5 g of peptone, 3 g of yeast extract, 3 g of ma / reto extract, 20 g / L of glucose / recose, pH 6.0) at 25 ° C, 72 750 L of cells were cultured aerobically for hours.
- the obtained cells were disrupted twice with a pressure homogenizer manufactured by Lanney and sealed with nitrogen gas at a disruption pressure of 140 MPa to prepare a cell disrupted liquid.
- the cell lysate was continuously extracted by a countercurrent three-stage continuous extraction device shown in Fig. 1.
- the capacity of the stirring tank was 630 L
- the capacity of the stationary separation tank was 200 L.
- the microbial cell lysate was supplied to the first-stage stirred tank, and isopropanol and n-hexane were supplied to each stage.
- the supply volume of the lysate was 2 L / min, and the supply volume of isopropanol and n-hexane was 1.3 L / min of isopropanol and ⁇ -hexane 3. It was set to 7 LZ. However, at this time, the solvent concentration in each stage was appropriately adjusted so that the isopropanol concentration was 5 to 50 vZv% and the n-hexane concentration was 25 to 65 VnV%.
- the extraction was performed at a temperature of 40 ° C and the treatment time was 6 hours.
- microorganism culturing reduced coenzyme.
- the oxidized coenzyme Q 10 can also be manufactured by a simple operation .
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003556541A JP4256782B2 (ja) | 2001-12-27 | 2002-12-27 | 補酵素q10の製造方法 |
CA2471763A CA2471763C (en) | 2001-12-27 | 2002-12-27 | Processes for producing coenzyme q10 |
EP02805906A EP1466983B1 (en) | 2001-12-27 | 2002-12-27 | Processes for producing coenzyme q10 |
US10/500,249 US20050069996A1 (en) | 2001-12-27 | 2002-12-27 | Processes for producing coenzyme q10 |
KR1020047010068A KR100913464B1 (ko) | 2001-12-27 | 2002-12-27 | 보효소 q10의 제조방법 |
AU2002357526A AU2002357526B2 (en) | 2001-12-27 | 2002-12-27 | Processes for producing coenzyme Q10 |
DE60225478.7T DE60225478C5 (de) | 2001-12-27 | 2002-12-27 | Verfahren zur herstellung des coenzyms q10 |
US11/981,181 US7910340B2 (en) | 2001-12-27 | 2007-10-31 | Processes for producing coenzyme Q10 |
US13/020,500 US9315839B2 (en) | 2001-12-27 | 2011-02-03 | Processes for producing coenzyme Q10 |
US15/076,025 US9926580B2 (en) | 2001-12-27 | 2016-03-21 | Process for producing coenzyme Q10 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001398545 | 2001-12-27 | ||
JP2001-398545 | 2001-12-27 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10500249 A-371-Of-International | 2002-12-27 | ||
US10/500,249 A-371-Of-International US20050069996A1 (en) | 2001-12-27 | 2002-12-27 | Processes for producing coenzyme q10 |
US11/981,181 Division US7910340B2 (en) | 2001-12-27 | 2007-10-31 | Processes for producing coenzyme Q10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003056024A1 true WO2003056024A1 (fr) | 2003-07-10 |
Family
ID=19189359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/013766 WO2003056024A1 (fr) | 2001-12-27 | 2002-12-27 | Procedes de production de la co-enzyme q10 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20050069996A1 (ja) |
EP (1) | EP1466983B1 (ja) |
JP (4) | JP4256782B2 (ja) |
KR (1) | KR100913464B1 (ja) |
CN (1) | CN100523205C (ja) |
AT (1) | ATE388236T1 (ja) |
AU (1) | AU2002357526B2 (ja) |
CA (1) | CA2471763C (ja) |
DE (1) | DE60225478C5 (ja) |
RU (1) | RU2298035C2 (ja) |
TW (2) | TWI305547B (ja) |
WO (1) | WO2003056024A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004051259A1 (ja) * | 2002-12-03 | 2004-06-17 | Shiseido Company, Ltd. | コエンザイムq−10およびその2電子還元体の分析方法ならびに分析システム |
WO2012011589A1 (ja) * | 2010-07-22 | 2012-01-26 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
US8952217B2 (en) | 2005-10-14 | 2015-02-10 | Metanomics Gmbh | Process for decreasing verbascose in a plant by expression of a chloroplast-targeted fimD protein |
JP2016208909A (ja) * | 2015-05-08 | 2016-12-15 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
WO2016208658A1 (ja) * | 2015-06-23 | 2016-12-29 | 株式会社カネカ | 還元型補酵素q10の製造方法 |
JPWO2019189290A1 (ja) * | 2018-03-28 | 2021-03-18 | 株式会社カネカ | 補酵素q10の製造方法 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI305547B (en) * | 2001-12-27 | 2009-01-21 | Kaneka Corp | Processes for producing coenzyme q10 |
TW200302055A (en) * | 2002-01-18 | 2003-08-01 | Kaneka Corp | Ubiquinol-enriched fat-containing foods |
TW200810776A (en) * | 2006-04-28 | 2008-03-01 | Kaneka Corp | Purification method of reduced coenzyme Q10 |
KR101406044B1 (ko) * | 2007-06-08 | 2014-06-12 | 한국생산기술연구원 | 감귤박을 탄소원으로 첨가한 배지에서 로도토룰라균의배양을 통한 코엔자임큐텐의 제조방법 |
EP2186789B1 (en) * | 2007-08-22 | 2013-12-25 | Kaneka Corporation | Method of producing reduced coenzyme q10 and method of stabilizing the same |
CN101307338B (zh) * | 2008-07-17 | 2012-04-25 | 任雷 | 还原型辅酶q10的制备方法 |
CN101519681B (zh) * | 2009-04-01 | 2012-11-07 | 宜都东阳光生化制药有限公司 | 一种辅酶q10的生产发酵工艺 |
SG10201402288RA (en) | 2009-05-11 | 2014-07-30 | Berg Llc | Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
WO2011130380A2 (en) * | 2010-04-13 | 2011-10-20 | Syracuse University | Coenzyme q10 production using sporidiobolus johnsonii |
US9655849B2 (en) | 2011-03-18 | 2017-05-23 | Particle Dynamics International, Llc | Solid particulate compositions comprising coenzyme Q10 |
WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
CN102557912B (zh) * | 2011-12-31 | 2015-01-07 | 内蒙古金达威药业有限公司 | 一种辅酶q10提取液的皂化方法 |
CN108982375B (zh) * | 2012-03-02 | 2022-03-04 | 博格有限责任公司 | 用于检测辅酶q10的方法和试剂盒 |
KR102279451B1 (ko) | 2013-04-08 | 2021-07-19 | 버그 엘엘씨 | 코엔자임 q10 병용 요법을 이용한 암 치료 |
KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
CN103819326B (zh) * | 2013-12-11 | 2016-08-17 | 湖南科源生物制品有限公司 | 一种从微生物中分离纯化辅酶q10的方法 |
CN105886562A (zh) * | 2016-05-31 | 2016-08-24 | 兰州天和生物催化技术有限公司 | 微生物发酵法制备辅酶q10的方法 |
WO2018003974A1 (ja) * | 2016-07-01 | 2018-01-04 | 株式会社カネカ | 補酵素q10の製造方法 |
CN108048496B (zh) * | 2017-12-25 | 2020-11-10 | 浙江新和成股份有限公司 | 氧化型辅酶q10的发酵生产方法、及由其制备而得的高含量氧化型辅酶q10 |
US10774350B2 (en) | 2017-12-25 | 2020-09-15 | Zhejiang Nhu Company Ltd. | Method for fermentative production of oxidized coenzyme Q10 |
WO2019208676A1 (ja) * | 2018-04-27 | 2019-10-31 | 株式会社カネカ | 補酵素q10の製造方法 |
CN108997153B (zh) * | 2018-07-25 | 2021-02-02 | 中国人民大学 | 从光合细菌中逐级提取多种高价值物质的方法 |
CN109055417B (zh) | 2018-08-28 | 2020-07-07 | 浙江新和成股份有限公司 | 一种重组微生物、其制备方法及其在生产辅酶q10中的应用 |
CN109762757B (zh) * | 2018-12-25 | 2020-01-07 | 神舟生物科技有限责任公司 | 一种高产辅酶q10类球红细菌及其诱变选育和应用 |
US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
CN112755589B (zh) * | 2021-02-23 | 2022-04-15 | 山东泰和水处理科技股份有限公司 | 精制辅酶q10的萃取方法及装置 |
CN115584357B (zh) * | 2022-11-02 | 2023-10-20 | 广东润和生物科技有限公司 | 一种辅酶q10的发酵提取方法 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS488836B1 (ja) * | 1970-03-31 | 1973-03-17 | ||
US3769170A (en) * | 1970-03-31 | 1973-10-30 | Ajinomoto Kk | Method of producing coenzyme q10 by microorganisms |
JPS54110388A (en) * | 1978-01-10 | 1979-08-29 | Kanegafuchi Chem Ind Co Ltd | Microbial preparation of coenzyme q10 |
JPS54119090A (en) * | 1978-03-07 | 1979-09-14 | Kyowa Hakko Kogyo Co Ltd | Preparation of coenzyme q10 by fermentation |
JPS5528A (en) * | 1978-05-29 | 1980-01-05 | Hiroshi Aida | Preparation of coenzyme q9 |
JPS5527A (en) * | 1978-05-25 | 1980-01-05 | Kanegafuchi Chem Ind Co Ltd | Microbiological preparation of coenzyme q10 |
JPS5521756A (en) * | 1978-08-04 | 1980-02-16 | Hiroshi Aida | Preparation of coenzyme q |
JPS5568295A (en) * | 1978-11-17 | 1980-05-22 | Godo Shiyusei Kk | Production of ubiquinone |
US4220719A (en) * | 1978-03-20 | 1980-09-02 | Ko Aida | Process for the production of Coenzyme Q10 |
JPS55148084A (en) * | 1979-05-08 | 1980-11-18 | Mitsubishi Gas Chem Co Inc | Incubation of microoranism |
JPS5655196A (en) * | 1979-10-08 | 1981-05-15 | Mitsubishi Gas Chem Co Inc | Method of culturing microorganism |
JPS56154994A (en) * | 1980-04-30 | 1981-11-30 | Sekisui Chem Co Ltd | Preparation of coenzyme q10 |
JPS56154996A (en) * | 1980-05-02 | 1981-11-30 | Sekisui Chem Co Ltd | Preparation of coenzyme q10 |
JPS5733599A (en) * | 1980-08-06 | 1982-02-23 | Mitsubishi Gas Chem Co Inc | Production of coenzyme q10 |
DD236552A1 (de) * | 1985-04-26 | 1986-06-11 | Akad Wissenschaften Ddr | Verfahren zur herstellung von ubichinon-10 |
JPH1057072A (ja) * | 1996-08-22 | 1998-03-03 | Alpha- Shokuhin Kk | ユビキノン−10の生成方法 |
EP1123979A1 (en) * | 1999-08-24 | 2001-08-16 | Kaneka Corporation | Process for producing coenzyme q 10? |
WO2002040682A1 (fr) * | 2000-11-20 | 2002-05-23 | Kaneka Corporation | Procede servant a preparer un coenzyme q¿10? |
WO2002052017A1 (fr) * | 2000-12-27 | 2002-07-04 | Kaneka Corporation | Procede relatif a la production de coenzyme q¿10? |
WO2002088365A1 (fr) * | 2001-04-25 | 2002-11-07 | Kaneka Corporation | Procede de production de coenzyme q¿10? |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB930752A (en) * | 1958-12-29 | 1963-07-10 | Merck & Co Inc | Preparation of coenzyme q-10 |
US3066080A (en) | 1961-03-22 | 1962-11-27 | Merck & Co Inc | Fermentation production of coenzyme q-10 |
JPS488836Y1 (ja) | 1969-11-28 | 1973-03-08 | ||
JPS4825517B1 (ja) * | 1970-08-24 | 1973-07-30 | ||
JPS4825517A (ja) | 1971-08-04 | 1973-04-03 | ||
JPS5452790A (en) * | 1977-10-04 | 1979-04-25 | Kanegafuchi Chem Ind Co Ltd | Preparation of coenzyme q |
JPS593197B2 (ja) | 1978-09-25 | 1984-01-23 | 十條製紙株式会社 | 補酵素q↓1↓0の製造法 |
JPS5771396A (en) * | 1980-10-07 | 1982-05-04 | Univ Nagoya | Preparation of coenzyme q10 |
JPS5770834A (en) * | 1980-10-17 | 1982-05-01 | Takara Shuzo Co Ltd | Preparation of coenzyme q |
AR228195A1 (es) * | 1981-08-19 | 1983-01-31 | Pfizer | Procedimiento microbiologico para la preparacion de hidroquinona |
JPS6075294A (ja) * | 1984-03-16 | 1985-04-27 | Nisshin Flour Milling Co Ltd | 補酵素qの製造法 |
JPS61271994A (ja) * | 1985-05-28 | 1986-12-02 | Mitsubishi Gas Chem Co Inc | 補酵素q↓1↓0の製造法 |
JPS6336789A (ja) * | 1986-07-29 | 1988-02-17 | Mitsubishi Gas Chem Co Inc | 補酵素q↓1↓0の製造法 |
JPS63317092A (ja) * | 1987-06-19 | 1988-12-26 | Mitsubishi Gas Chem Co Inc | 補酵素q↓1↓0の製造法 |
JPS63102691A (ja) | 1987-09-11 | 1988-05-07 | Nisshin Flour Milling Co Ltd | 補酵素q↓1↓0の製造法 |
JPH088836B2 (ja) | 1991-10-31 | 1996-01-31 | 社団法人長野県農村工業研究所 | 酵素により特性を改変した澱粉粒の利用方法 |
CA2207093A1 (en) * | 1994-12-06 | 1996-06-13 | Ryan Pharmaceuticals, Inc. | Water soluble ubiquinone compositions, prodrugs, and methods relating thereto |
JP3889481B2 (ja) | 1996-08-16 | 2007-03-07 | 株式会社カネカ | 医薬組成物 |
JP3926888B2 (ja) * | 1997-05-27 | 2007-06-06 | 株式会社カネカ | コレステロール低下剤 |
JPH1156372A (ja) | 1997-08-27 | 1999-03-02 | Alpha- Shokuhin Kk | ユビキノン−10の生成方法 |
AU7686000A (en) | 1999-10-14 | 2001-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing ubiquinone-10 |
JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
DE60238056D1 (de) * | 2001-07-13 | 2010-12-02 | Kaneka Corp | Verfahren zum kristallisieren von reduziertem coenzym q10 aus wässriger lösung |
TW200604159A (en) * | 2001-07-13 | 2006-02-01 | Kaneka Corp | Method of producing reduced coenzyme Q10 as oily product |
TWI310029B (ja) * | 2001-07-13 | 2009-05-21 | Kaneka Corp | |
TWI237018B (en) * | 2001-07-13 | 2005-08-01 | Kaneka Corp | Method of producing reduced coenzyme Q10 crystals |
TWI237019B (en) * | 2001-07-13 | 2005-08-01 | Kaneka Corp | Method of producing reduced coenzyme Q10 |
TWI235146B (en) * | 2001-07-16 | 2005-07-01 | Kaneka Corp | Method of stabilizing reduced coenzyme q10 and method of acidic crystallization |
JP3822479B2 (ja) * | 2001-10-10 | 2006-09-20 | 株式会社カネカ | 還元型補酵素q水溶液の安定化組成 |
TWI329510B (en) * | 2001-10-10 | 2010-09-01 | Kaneka Corp | Method of stabilizing reduced coenzyme q10 |
TWI305547B (en) | 2001-12-27 | 2009-01-21 | Kaneka Corp | Processes for producing coenzyme q10 |
JP3781118B2 (ja) | 2003-03-03 | 2006-05-31 | セイコーエプソン株式会社 | 配線基板の製造方法 |
-
2002
- 2002-12-26 TW TW091137404A patent/TWI305547B/zh not_active IP Right Cessation
- 2002-12-26 TW TW097132867A patent/TWI349039B/zh not_active IP Right Cessation
- 2002-12-27 KR KR1020047010068A patent/KR100913464B1/ko active IP Right Grant
- 2002-12-27 AT AT02805906T patent/ATE388236T1/de not_active IP Right Cessation
- 2002-12-27 RU RU2004122912/13A patent/RU2298035C2/ru not_active IP Right Cessation
- 2002-12-27 US US10/500,249 patent/US20050069996A1/en not_active Abandoned
- 2002-12-27 AU AU2002357526A patent/AU2002357526B2/en not_active Expired
- 2002-12-27 CN CNB028262417A patent/CN100523205C/zh not_active Expired - Lifetime
- 2002-12-27 WO PCT/JP2002/013766 patent/WO2003056024A1/ja active IP Right Grant
- 2002-12-27 JP JP2003556541A patent/JP4256782B2/ja not_active Expired - Fee Related
- 2002-12-27 CA CA2471763A patent/CA2471763C/en not_active Expired - Lifetime
- 2002-12-27 DE DE60225478.7T patent/DE60225478C5/de not_active Expired - Lifetime
- 2002-12-27 EP EP02805906A patent/EP1466983B1/en not_active Expired - Lifetime
-
2007
- 2007-10-31 US US11/981,181 patent/US7910340B2/en not_active Expired - Lifetime
-
2008
- 2008-05-07 JP JP2008121453A patent/JP5074287B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-03 US US13/020,500 patent/US9315839B2/en not_active Expired - Fee Related
-
2012
- 2012-04-17 JP JP2012094126A patent/JP5788831B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-18 JP JP2014125185A patent/JP2014166191A/ja active Pending
-
2016
- 2016-03-21 US US15/076,025 patent/US9926580B2/en not_active Expired - Lifetime
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS488836B1 (ja) * | 1970-03-31 | 1973-03-17 | ||
US3769170A (en) * | 1970-03-31 | 1973-10-30 | Ajinomoto Kk | Method of producing coenzyme q10 by microorganisms |
JPS54110388A (en) * | 1978-01-10 | 1979-08-29 | Kanegafuchi Chem Ind Co Ltd | Microbial preparation of coenzyme q10 |
JPS54119090A (en) * | 1978-03-07 | 1979-09-14 | Kyowa Hakko Kogyo Co Ltd | Preparation of coenzyme q10 by fermentation |
US4220719A (en) * | 1978-03-20 | 1980-09-02 | Ko Aida | Process for the production of Coenzyme Q10 |
JPS5527A (en) * | 1978-05-25 | 1980-01-05 | Kanegafuchi Chem Ind Co Ltd | Microbiological preparation of coenzyme q10 |
JPS5528A (en) * | 1978-05-29 | 1980-01-05 | Hiroshi Aida | Preparation of coenzyme q9 |
JPS5521756A (en) * | 1978-08-04 | 1980-02-16 | Hiroshi Aida | Preparation of coenzyme q |
JPS5568295A (en) * | 1978-11-17 | 1980-05-22 | Godo Shiyusei Kk | Production of ubiquinone |
JPS55148084A (en) * | 1979-05-08 | 1980-11-18 | Mitsubishi Gas Chem Co Inc | Incubation of microoranism |
JPS5655196A (en) * | 1979-10-08 | 1981-05-15 | Mitsubishi Gas Chem Co Inc | Method of culturing microorganism |
JPS56154994A (en) * | 1980-04-30 | 1981-11-30 | Sekisui Chem Co Ltd | Preparation of coenzyme q10 |
JPS56154996A (en) * | 1980-05-02 | 1981-11-30 | Sekisui Chem Co Ltd | Preparation of coenzyme q10 |
JPS5733599A (en) * | 1980-08-06 | 1982-02-23 | Mitsubishi Gas Chem Co Inc | Production of coenzyme q10 |
DD236552A1 (de) * | 1985-04-26 | 1986-06-11 | Akad Wissenschaften Ddr | Verfahren zur herstellung von ubichinon-10 |
JPH1057072A (ja) * | 1996-08-22 | 1998-03-03 | Alpha- Shokuhin Kk | ユビキノン−10の生成方法 |
EP1123979A1 (en) * | 1999-08-24 | 2001-08-16 | Kaneka Corporation | Process for producing coenzyme q 10? |
WO2002040682A1 (fr) * | 2000-11-20 | 2002-05-23 | Kaneka Corporation | Procede servant a preparer un coenzyme q¿10? |
WO2002052017A1 (fr) * | 2000-12-27 | 2002-07-04 | Kaneka Corporation | Procede relatif a la production de coenzyme q¿10? |
WO2002088365A1 (fr) * | 2001-04-25 | 2002-11-07 | Kaneka Corporation | Procede de production de coenzyme q¿10? |
Non-Patent Citations (13)
Title |
---|
DATABASE MEDLINE [online] KOCHOVA-KRATOCHVILOVA A. ET AL.: "Die beziehungen innerhalb der gattung cryptococcus (sanfelice) vuillemin", XP002967050, Database accession no. 77107492 * |
NATORI Y. ET AL.: "Studies in the metabolites produced by facultative methanol oxidizing bacteria. Part I. Production of coenzyme Q10 by pseudomonas N842", AGRIC. BIOL. CHEM., vol. 42, no. 9, 1978, pages 1799 - 1800, XP002967049 * |
NATORI Y. ET AL.: "Studies on metabolites produced by facultative methanol-oxidizing bacteria. Part V. Enhancement of coenzyme Q10 accumulation by mutation and effects of medium components on the formation of coenzyme Q homologs by pseudomonas N842 and mutants", AGRIC. BIOL. CHEM., vol. 45, no. 10, 1981, pages 2175 - 2182, XP002967048 * |
OHTA H.: "Agromonas oligotrophica gen. nov., sp. nov., a nitrogen-fixing oligotrophic bacterium", ANTONIE VAN LEEUWENHOEK, vol. 49, no. 4-5, 1983, pages 429 - 446, XP002967042 * |
SAKATO K. ET AL.: "Agitation-aeration studies on coenzyme Q-10 production using rhodopseudomonas spheroides", BIOTECHNOL. APPL. BIOCHEM., vol. 16, no. 1, 1992, pages 19 - 28, XP002967047 * |
URAKAMI T. ET AL.: "Production of isoprenoid compounds in the faculative methylotroph protomonas extroquens", J. FERMENT. TECHNOL., vol. 66, no. 3, 1988, pages 323 - 332, XP002967045 * |
URAKAMI T. ET AL.: "Production of ubiquinone and bacteriochlorophyll alpha by rhodobacter sphaeroides and rhodobacter sulfidophilus", JOURNAL OF FERMENTATION AND BIOENGINEERING, vol. 76, no. 3, 1993, pages 191 - 194, XP002967044 * |
URAKAMI T. ET AL.: "Transfer of pseudomonas-aminovorans den Dooren de Jong 1926 to aminobacter gen. nov. as aminobacter aminovorans comb. nov. and description of aminobacter aganoensis sp. nov. and aminobacter niigataensis sp. nov.", INT. J. SYST. BACTERIOL., vol. 42, no. 1, January 1992 (1992-01-01), pages 84 - 92, XP002967043 * |
WAKAO N. ET AL.: "Acidiphilium multivorm sp. nov., an acidophilic chemoorganotrophic bacterium from pyritic acid mine drainage", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 40, no. 2, 1994, pages 143 - 159, XP002967041 * |
YABUUCHI E. ET AL.: "Proposals of sphingomonas paucimobilis gen. nov. and comb. nov., sphingomonas parapaucimobilis sp. nov., sphingomonas yanoikuyae sp. nov., sphingomonas adhaesiva sp. nov., sphingomonas capsulata comb. nov. and two genospecies of the genus sphingomonas", MICROBIOLOGY AND IMMUNOLOGY, vol. 34, no. 2, 1990, pages 99 - 119, XP000901217 * |
YAMADA Y. ET AL.: "The coenzyme Q system in strains of trichosporon species and related organisms", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 28, no. 4, 1982, pages 355 - 358, XP002967046 * |
YOSHIDA H. ET AL.: "Production of ubiquinone-10 using bacteria", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 44, no. 1, 1998, pages 19 - 26, XP009003546 * |
ZENTRALBLATT FUER BAKTERIOLOGIE, PARASITENKUNDE, INFEKTIONSKRANKHEITEN UND HYGIENE. ZWEITE NATURWISSENSCHAFTLICHE ABT.: ALLGEMEINE, LANDWIRTSCHAFTLICHE UND TECHNISCHE MIKROBIOLOGIE, vol. 131, no. 7, 1976, pages 610 - 631 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004051259A1 (ja) * | 2002-12-03 | 2004-06-17 | Shiseido Company, Ltd. | コエンザイムq−10およびその2電子還元体の分析方法ならびに分析システム |
US7374901B2 (en) | 2002-12-03 | 2008-05-20 | Shiseido Company Ltd. | Method of analyzing coenzyme Q-10 and two-electron reduction product thereof and analysis system |
US8952217B2 (en) | 2005-10-14 | 2015-02-10 | Metanomics Gmbh | Process for decreasing verbascose in a plant by expression of a chloroplast-targeted fimD protein |
WO2012011589A1 (ja) * | 2010-07-22 | 2012-01-26 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
JP5016734B2 (ja) * | 2010-07-22 | 2012-09-05 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
US9006493B2 (en) | 2010-07-22 | 2015-04-14 | Kaneka Corporation | Method for manufacturing a fat-soluble bioactive substance |
JP2016208909A (ja) * | 2015-05-08 | 2016-12-15 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
WO2016208658A1 (ja) * | 2015-06-23 | 2016-12-29 | 株式会社カネカ | 還元型補酵素q10の製造方法 |
JPWO2016208658A1 (ja) * | 2015-06-23 | 2018-04-12 | 株式会社カネカ | 還元型補酵素q10の製造方法 |
US10239811B2 (en) | 2015-06-23 | 2019-03-26 | Kaneka Corporation | Process for producing reduced coenzyme Q10 |
JPWO2019189290A1 (ja) * | 2018-03-28 | 2021-03-18 | 株式会社カネカ | 補酵素q10の製造方法 |
JP7421471B2 (ja) | 2018-03-28 | 2024-01-24 | 株式会社カネカ | 補酵素q10の製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003056024A1 (fr) | Procedes de production de la co-enzyme q10 | |
EP2597156B1 (en) | Method for manufacturing a fat-soluble bioactive substance | |
US20140170720A1 (en) | Method for producing retinoid from microorganism | |
EP3480317A1 (en) | Method for producing coenzyme q10 | |
Tramper et al. | Xanthine oxidase activity of arthrobacter x-4 cells immobilized in glutaraldehyde-crosslinked gelatin | |
CN113355368B (zh) | 水溶化碳笼在黑曲霉发酵制备柠檬酸中的应用及应用方法 | |
JP4744916B2 (ja) | 光学活性アルキルアルコール誘導体の単離取得方法 | |
Karakaya et al. | Natural vanillin production from isoeugenol by using pseudomonas putida in biphasic bioconversion medium | |
JP2013078291A (ja) | 微生物によるコエンザイムq10の製造法 | |
Kanaya et al. | Process for producing reduced coenzyme Q 10 | |
US20210032666A1 (en) | Method for producing coenzyme q10 | |
EP0443925A1 (fr) | Procédé d'obtention d'irone par voie microbiologique | |
EP2551351A1 (en) | Process for production of optically active (R)-(-)-1-(2,4-dichloro-phenyl)-2-imidazole-1-yl-ethanol | |
JP2016208909A (ja) | 脂溶性生理活性物質の製造方法 | |
US20210238637A1 (en) | Method for producing coenzyme q10 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003556541 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2471763 Country of ref document: CA Ref document number: 20028262417 Country of ref document: CN Ref document number: 2002357526 Country of ref document: AU Ref document number: 1020047010068 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 918/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002805906 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004122912 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002805906 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10500249 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002805906 Country of ref document: EP |